

Supplement

Supplement 1: Patients characteristics stratified per DMARD group

Variables	Patients without DMARDs (n=16)	Patients with csDMARDs (n=121)	Patients with bDMARDs (n=280)	Patients with tsDMARDs (n=24)
Age, y	58.7 (10.3)	57.3 (11.7)	52.5 (12.7)	53.0 (13.7)
Women, No. (%)	12 (75)	78 (64.5)	168 (60)	14 (58.3)
Education ≥12 years	4 (26.7)	39 (34.2)	87 (33.1)	7 (29.2)
Rheumatoid Arthritis, No. (%)	8 (50)	53 (43.8)	79 (28.2)	16 (66.7)
Axial Spondyloarthritis, No. (%)	4 (25)	8 (6.6)	108 (38.6)	0
Psoriatic Arthritis, No. (%)	2 (12.5)	10 (8.3)	42 (15.0)	7 (29.2)
Other diagnoses, No. (%)	2 (12.5)	50 (41.4)	51 (18.2)	1 (4.2)
Disease duration, y	11.5 (8.6)	6.1 (6.9)	11.3 (9.2)	10.2 (8.9)
CRP, mg/l	0.4 (0.4)	0.4 (0.7)	0.4 (0.7)	0.4 (0.5)
Patient global, NRS 0-10	4.13 (2.5)	3.91 (2.49)	4.2 (2.4)	4.1 (2.8)
CDAI	11.25 (8.1)	10.33 (9.7)	11.6 (8.8)	8 (7.7)
CDAI ≥22.1, n (%)	0	6 (9.8)	14 (11.6)	0
BASDAI	5.1 (2.2)	2.95 (1.8)	3.2 (2.2)	0
BASDAI ≥4, n (%)	2 (50)	3 (37.5)	56 (52.8)	0
HAQ	0.85 (0.49)	1.05 (0.6)	1.2 (0.6)	1.1 (0.5)
BASFI	4.1 (2.9)	2.21 (2.1)	3.8 (2.3)	0
HADS-A	5.4 (4.0)	6.3 (4.2)	6.7 (3.9)	6.5 (4.2)

HADS-D	5.06 (3.7)	6.3 (4.3)	6.1 (4.2)	6.0 (4.3)
Patients worried about contracting COVID-19, NRS 0-10	6.53 (2.2)	6.4 (3.1)	6.0 (2.9)	6.8 (2.5)
Individual risk to get a worse COVID-19 infection, NRS 0-10	7.38 (2.1)	7.1 (2.5)	7.0 (2.4)	7.3 (2.7)
Personal assignment to a risk group, n (%)	9 (56.3)	86 (71.1)	214 (76.4)	21 (87.5)
Prior COVID-19 infection, n (%)	2 (12.5)	4 (3.3)	14 (5.0)	2 (8.3)
Willingness to be vaccinated against SARS-CoV-2, NRS 0-10	9.3 (1.5)	8.7 (2.5)	8.5 (2.5)	7.9 (3.2)
Definitely willing to receive SARS-CoV-2 vaccine, n (%)	15 (93.8)	103 (85.1)	221 (78.9)	18 (75.0)
Probably willing to receive SARS-CoV-2 vaccine, n (%)	0	7 (0.5)	38 (13.5)	3 (12.5)
Unwilling to receive SARS-CoV-2 vaccine, n (%)	1 (6.2)	11 (9.1)	21 (7.5)	3 (12.5)
Confidence in safety of SARS-CoV-2 vaccine, NRS 0-10	7.63 (3.2)	7.2 (2.8)	6.6 (2.7)	6.3 (3.4)
Concerns about side effects of SARS-CoV-2 vaccine, NRS 0-10	4.69 (3.5)	5.2 (3.3)	5.5 (3.2)	5.1 (3.0)
Vaccine uptake of SARS-CoV-2 vaccine in the past, n (%)	2 (12.5)	9 (7.4)	17 (6.1)	1 (4.2)
Vaccine uptake of influenza in the past, n (%)	9 (56.3)	82 (67.8)	191 (68.7)	16 (66.7)
Vaccine uptake of pneumococci in the past, n (%)	7 (43.8)	60 (49.6)	163 (59.3)	13 (54.2)

Supplement 2: Patients characteristics of patients who provided data and who did not provide data on attitudes to vaccines

Variables	Patients completed questionnaire on facilitators and barriers (n=441)	Patients who did not complete questionnaire on facilitators and barriers (n=73)
Age, y	54.1 (12.6)	58.6 (13.6)
Women, No. (%)	272 (61.7)	42 (57.5)
Education ≥12 years	137 (31.3%)	17 (23.3)
Rheumatoid Arthritis, No. (%)	156 (35.4)	36 (49.3)
Axial Spondyloarthritis, No. (%)	120 (27.2)	14 (19.2)
Psoriatic Arthritis, No. (%)	61 (13.8)	11 (15.1)
Other diagnoses, No. (%)	104 (23.6)	12 (16.4)
Disease duration, y	9.8 (8.9)	9.5 (9.6)
Treatment, csDMARD, No. (%)	121 (27.4)	25 (34.2)
Treatment, bDMARD, No. (%)	280 (63.5)	37 (50.7)
Treatment, tsDMARD, No. (%)	24 (5.4)	9 (12.3)
CRP, mg/L, n=440	0.4 (0.7)	0.4 (0.5)
Patient global, NRS 0-10	4.1 (2.5)	3.7 (2.3)
CDAI	11.1 (9.0), n=193	8.3 (8.2), n=31
CDAI ≥22.1, n (%)	20 (10.4)	3 (9.7)
BASDAI	3.8 (2.2), n=118	3.7 (1.7), n=14
BASDAI ≥4, n (%)	61 (51.7)	4 (28.6)
HAQ, n=317	1.1 (0.7)	1.2 (0.7)
BASFI, n=118	3.8 (2.3)	3.7 (2.3)
HADS-A, n=436	6.6 (4.0)	6.0 (4.3)
HADS-D, n=436	5.8 (4.3)	5.4 (4.4)
Patients worried about contracting COVID-19, NRS 0-10	6.2 (3.0)	5.6 (3.1)
Individual risk to get a worse COVID-19 infection, NRS 0-10	7.1 (2.5)	7.1 (2.7)
Personal assignment to a risk group, n (%)	330 (74.8)	50 (68.5)
Prior COVID-19 infection, n (%)	22 (5.0)	0 (0)
Willingness to be vaccinated against SARS-CoV-2, NRS 0-10	8.6 (2.5)	8.4 (2.8)
Definitely willing to receive	357 (81.5)	52 (77.6)

SARS-CoV-2 vaccine, n (%)		
Probably willing to receive SARS-CoV-2 vaccine, n (%)	48 (11.0)	9 (13.4)
Unwilling to receive SARS-CoV-2 vaccine, n (%)	33 (7.5)	6 (9.0)
Confidence in safety of SARS-CoV-2 vaccine, NRS 0-10	6.8 (2.8)	6.7 (2.9)
Concerns about side effects of SARS-CoV-2 vaccine, NRS 0-10	5.4 (3.3)	4.8 (3.3)
Vaccine uptake of SARS-CoV-2 vaccine in the past, n (%)	29 (6.6)	4 (5.5)
Vaccine uptake of influenza in the past, n (%)	279 (63.3)	42 (57.5)
Vaccine uptake of pneumococci in the past, n (%)	225 (51)	42 (50.7)